The Scientific Board of BioJeL

The Scientific Board of BioJeL is responsible for examining and validating all submitted requests according to specific criteria.

The requests analysis proceeds in 3 steps:

  • Technical feasibility analysis by the Technical Committee of the CRB-BioJeL
  • Scientific Expertise by the Scientific Council of the CRB-BioJeL
  • Final validation of the request by the Steering Committee of the CRB-BioJeL

The analytical criteria used by the Scientific Board for these evaluations relate to several items:

  • Technical feasibility (time, quantities)
  • Compatibility with the strategy of BioJeL (compatibility with the priority research programs defined by BioJeL and the Jérôme Lejeune Institute, with prioritization according to the type of request. For example, scientific partnerships are favoured over scientific services)
  • Checking of the legal and regulatory obligations of the person or entity making the request
  • Availability of the samples with respect to consent (patient's non-opposition, or agreement for exporting samples)
  • Agreement of the person or entity responsible for initiating the collection of the samples concerned
  • Priority given to the type of person or entity making the request (hospital establishment, national or international organisation)
  • Availability according to priority rights of other users (Is the being constituded at the request of a researcher? Is the collection under embargo until the publication of the first results?)
  • Conditions of availability (billing, scientific partnership, industrial property rights)
  • Compatibility of the request with the ethics policy of the Jérôme Lejeune Institute and Foundation

Composition of the Technical Committee:

  • The person in charge and the technician of the CRB-BioJeL

Composition of the Scientific Committee

  • André MEGARBANE – Professor of Medical Genetics at the Faculty of Medicine, Saint Joseph University of Beirut
  • Clotilde MIRCHER – Medical Geneticist and head of the consultation at the Jérôme Lejeune Institute
  • Paul BASTARD, Pediatrician, researcher, Hôpital Saint-Louis – Laboratory of Human Genetics of Infectious Diseases (Institut Imagine, Paris)
  • François MOUTON-LIGER – Researcher INSERM UMR-S144, Lariboisière Hospital – Specialist in neurodegenerative diseases
  • Pierre-Marie SINET – Doctor INSERM Institut Paul Broca – Specialist in Clinical Genetics, Molecular Genetics and Biochemistry

Composition of the Management Committee:

  • Jean-Marie SCHMITZ – President of the Jérôme Lejeune Institute
  • Grégoire FRANCOIS-DAINVILLE – General Director of the Jérôme Lejeune Institute
  • Jean-Marie LE MENE – President of the Jérôme Lejeune Foundation
  • Thierry de la VILLEJEGU – General Director
  • Catherine LEMONNIER – Director of Research of the Jérôme Lejeune Foundation